Morgan Stanley
CNSP icon

Morgan Stanley’s CNS Pharmaceuticals CNSP Stock Holding History

Morgan Stanley’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28
Closed -$252 – 8254
2025
Q3 		$252 Buy
+28
New +$225 ﹤0.01% 7580
2024
Q3 		– Hold
0
– -$3 – 7943
2024
Q2 		– Hold
0
– – – 7823
2024
Q1 		– Hold
0
– – – 7689
2023
Q4 		– Hold
0
– – – 7365
2023
Q3 		– Hold
0
– – – 7464
2022
Q1 		– Hold
0
– -$4K – 7982
2021
Q4 		– Hold
0
– – – 7680
2021
Q3 		– Hold
0
– – – 7388
2021
Q2 		– Hold
0
– – – 6925
2021
Q1 		– Hold
0
– – – 6572
2020
Q4 		– Hold
0
– – – 6402
2020
Q3 		– Hold
0
– – – 6022
2020
Q2 		– Hold
0
– -$4K – 6613
2020
Q1 		– Hold
0
– – – 6265
2019
Q4 		– Hold
0
– – – 6658

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Morgan Stanley's CNSP Position: Q4 2025 in Review

Morgan Stanley sold out of CNS Pharmaceuticals (CNSP) in Q4 2025, closing a stake of 28 shares — an estimated $252 sold.

Morgan Stanley first reported a position in CNSP in Q3 2025 and held it in 1 quarter. The position peaked at $252 in Q3 2025. 10 funds tracked by Wall St. Rank hold CNSP as of Q4 2025.

  • Morgan Stanley reported no remaining CNS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Morgan Stanley sold 28 CNS Pharmaceuticals shares in Q4 2025, an estimated $252.
  • Morgan Stanley first reported a position in CNS Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Morgan Stanley's CNS Pharmaceuticals position peaked at $252 in Q3 2025.
  • 10 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.